- Home
- COHN vs ALGS Comparison
COHN vs ALGS Comparison
Compare COHN & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COHN | ALGS |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.7M | 34.6M |
| IPO Year | 2003 | 2020 |
Fundamental Metrics
Financial Performance| Metric | COHN | ALGS |
|---|---|---|
| Price | $10.50 | $5.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $52.38 |
| AVG Volume (30 Days) | 9.0K | ★ 37.4K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | ★ 9.60% | N/A |
| EPS Growth | ★ 5537.50 | 88.30 |
| EPS | ★ 1.36 | N/A |
| Revenue | ★ $275,564,000.00 | $2,186,000.00 |
| Revenue This Year | N/A | $1,562.10 |
| Revenue Next Year | $0.39 | N/A |
| P/E Ratio | $7.66 | ★ N/A |
| Revenue Growth | ★ 246.19 | N/A |
| 52 Week Low | $9.19 | $3.98 |
| 52 Week High | $32.60 | $13.69 |
Technical Indicators
Market Signals| Indicator | COHN | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 46.87 | 43.61 |
| Support Level | $9.91 | $5.18 |
| Resistance Level | $11.65 | $6.91 |
| Average True Range (ATR) | 0.37 | 0.32 |
| MACD | 0.12 | 0.02 |
| Stochastic Oscillator | 64.38 | 37.50 |
Price Performance
Historical ComparisonAbout COHN Cohen & Company Inc.
Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.